Febuxostat (Uloric) and its problem with cardiovascular mortality

January 16, 2109 – Despite drug safety problems of cardiovascular mortality with Febuxostat (Uloric), the benefits might still be seen to outweigh risks for selected gout patients. This notion may become more and disputed over time, however, for obvious reasons. Febuxostat (Uloric) was approved by the American Food and Drug Administration (FDA) in 2009 for the chronic management of hyperuricemia in patients with gout. One condition of the approval of Febuxostat (Uloric) in 2009 was that a postmarketing safety study be conducted by Takeda Pharmaceuticals America, Inc. The postmarketing safety trial required by the FDA was called Cardiovascular Safety of Febuxostat (Uloric) and Allopurinol in Patients with Gout and Cardiovascular Comorbidities (CARES).
In March 2018 it was announced that this CARES trial found that Febuxostat (Uloric) was inexplicably linked to more cardiac deaths than was Allopurinol, the mainstay drug for patients with gout and cardiovascular disease. As a consequence, on January 10, 2019, the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee panelists discussed the potential biological mechanisms behind cardiovascular (CV) events associated with the use of Febuxostat (Uloric) and its seemingly heightened risk for unwanted cardiovascular events.

The panelists came to the conclusion that for the general population with gout, the benefits of Febuxostat (Uloric) would not outweigh the risks (particularly cardiovascular events) when compared to Allopurinol, one of the standard treatments in patients with gout. In contrast, they proposed that the benefits of urate-lowering Febuxostat (Uloric) outweigh its risks for selected gout patients, though only for unrestricted access only as a second-line therapy, mostly for individuals who have had a serious skin reaction to or otherwise “absolutely don’t tolerate” Allopurinol, the mainstay xanthine oxidase inhibitor for uric acid reduction.

In this context, it is noteworthy that Febuxostat (Uloric)’s label already warns of increased risk of gout flares with initiation of therapy, cardiovascular events, hepatic toxicity, and serious skin reactions. Panelists further recommended several regulatory actions such as an additional black box warning and a change in the indication to label Febuxostat (Uloric) as a second-line therapy after Allopurinol only. They kept it open, if even a recall of Febuxostat (Uloric) could be considered.

Further to the status at the time of this writing, the FDA has now added a “Boxed Warning” to the drug label of Febuxostat (Uloric) due to the obvious increased risk of death for patients under Febuxostat (Uloric) and introduce a new, strengthened patient Medication Guide. FDA  also limits the approved use of Uloric to certain patients who are not treated effectively or experience severe side effects with Allopurinol.  See here the according safety communication by the FDA as of February 02, 2019.

See here an video introductory to gout:

Print Friendly, PDF & Email

Tags: , , , , , , , ,
About the Author
Joseph Gut - thasso Ph.D.; Professor in Pharmacology and Toxicology. Senior expert in theragenomic and personalized medicine and individualized drug safety. Senior expert in pharmaco- and toxicogenetics. Senior expert in human safety of drugs, chemicals, environmental pollutants, and dietary ingredients.

Your opinion


@peepso_user_1(thassodotcom) This was about time. That is what Boxed Warnings are for.
1 year ago 1 year ago

thasso: conditions

thasso: newest tweets

thasso: recent comments

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • The genetics of side-effects November 25, 2020
    Henk-Jan Guchelaar knows all too well the serious problems that the side-effects of medication can cause. As a professor of clinical pharmacy at the University of Leiden in the Netherlands, he has spent the last two decades trying to get the link between medicine and our genes recognised more widely.
  • Gene donors at high risk for cancer received feedback November 25, 2020
    Researchers at the Estonian Genome Center at the University of Tartu studied how people at high risk for breast, ovarian or prostate cancer responded to the feedback of genetic findings. Gene donors who chose to receive results appreciated being contacted and considered the information provided to be valuable. Authors find that knowing more about people's […]
  • Researchers reveal how genetic variations are linked to COVID-19 disease severity November 25, 2020
    Even as tens of thousands of Americans test positive for COVID-19 each day, physicians still aren't sure why some people experience mild to no symptoms while others become critically ill. New research led by Robert E. Gerszten, MD, Chief of the Division of Cardiovascular Medicine at Beth Israel Deaconess Medical Center (BIDMC) sheds new light […]
  • Study identifies new functions in the gene that causes Machado-Joseph disease November 25, 2020
    Ataxia is a minority disease with genetic origins, known for its neuromuscular alterations due to the selective loss of neurons in the cerebellum, the organ of our nervous systems which controls movement and balance. UB researchers have identified new functions in the ataxin 3 gene (ATXN3)–which causes Machado-Joseph disease, the most common type of ataxia– […]
  • BICRA gene provides answers to patients, doctors and scientists November 23, 2020
    Physicians and scientists are constantly on the lookout for new disease genes that can help them understand why patients have undiagnosed medical problems. Often the first clues come from genetic testing that reveals a change or mutation in a gene that they see in a child but not their parents. This is exactly what led […]
  • Understanding traditional Chinese medicine can help protect species November 26, 2020
    Demystifying traditional Chinese medicine for conservationists could be the key to better protecting endangered species like pangolins, tigers and rhino, according to University of Queensland-led researchers. UQ PhD candidate Hubert Cheung said efforts to shift entrenched values and beliefs about Chinese medicine are not achieving conservation gains in the short term.
  • Satellite images confirm uneven impact of climate change November 26, 2020
    University of Copenhagen researchers have been following vegetation trends across the planet's driest areas using satellite imagery from recent decades. They have identified a troubling trend: Too little vegetation is sprouting up from rainwater in developing nations, whereas things are headed in the opposite direction in wealthier ones. As a result, the future could see […]
  • Survival protein may prevent collateral damage during cancer therapy November 25, 2020
    Australian researchers have identified a protein that could protect the kidneys from 'bystander' damage caused by cancer therapies. The 'cell survival protein', called BCL-XL, was required in laboratory models to keep kidney cells alive and functioning during exposure to chemotherapy or radiotherapy. Kidney damage is a common side effect of these widely used cancer therapies, […]
  • New discovery by SMART allows early detection of shade avoidance syndrome in plants November 25, 2020
    Researchers from Singapore-MIT Alliance for Research and Technology (SMART) have developed a tool that allows early detection of shade avoidance syndrome (SAS) in plants using Raman spectroscopy in significantly less time compared to conventional methods. The discovery can help farmers better monitor plant health and lead to improved crop yield.
  • Psychological factors contributing to language learning November 25, 2020
    Motivation for language learning is a system of cognitive, emotional, and personality-related characteristics.